Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMED.L Regulatory News (MED)

  • There is currently no data for MED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results - Replacement

30 Sep 2008 11:19

RNS Number : 6674E
MicroEmissive Displays Group PLC
30 September 2008
 



Correction:

The following release is a correction to the RNS announcement 6241E of 30 September 2008, regarding an amendment to Note 1 of the accounts, where 25 September is replaced by 29 September.

For Immediate Release: 30 September 2008

MicroEmissive Displays Group plc

("MED", the "Company" or "Group")

Interim Results for the Six Months Ended 30 June 2008

MED, the AIM listed designer and manufacturer of low power light emitting polymer displays, announces its unaudited results for the six months ended 30 June 2008. 

Overview

Good progress at volume manufacturing facility

Nine design wins for our unique eyescreen® product

Ongoing discussions with global digital camera manufacturers

Significant MOU contracts signed with Kaga Components Ltd and Universal Scientific Industrial Co. Ltd 

Appointment of Glenn Collinson as Non-Executive Director

Revenues for the period were £377,000 (2007: £0)

In discussions with interested parties with regard to re-financing the business

Commenting on the results, George Elliott, Chairman of MED, said: "MED's technology provides unique benefits which are being demanded by the market. Progress with our customer base is slower than expected but is progressing and management continue to believe that the market opportunities for the Company remain very significant."

He added: "As announced on 1 August 2008, the Company has, however, experienced slower than anticipated development of the market for consumer head mounted displays. Against this backdrop, the Board is reviewing its strategic options for the financing of the Company, which may include considering proposals for an offer for the Company."

For further information, please visit www.microemissive.com contact:

MicroEmissive Displays

Bill Miller, Chief Executive 

Graeme N Walker, Finance Director

0131 650 7764

Tavistock Communications

Matt Ridsdale 

Andrew Dunn

020 7920 3150

Arbuthnot Securities

Neil Kirton

John Prior

020 7012 2000

  Chairman's Statement 

Introduction

The period under review has seen good progress at our manufacturing facility and increased activity in developing partner and potential customer relationships. As announced on 1 August 2008, the Company has, however, experienced slower than anticipated development of the market for consumer head mounted displays. Against this backdrop, the Board is reviewing its strategic options for the financing of the Company, which may include considering proposals for an offer for the Company.

Operational Review

Following the opening of our state-of-the-art production facility in Dresden, Germany, volume manufacturing has been achieved, with the quality of yields at the site outperforming our estimates. Over 100,000 units have now been shipped.

Customers/Partners

In May 2008, we announced nine design wins for our unique eyescreen® product. These agreements involve working with partners to design our component into a range of different electronic products. The Board believes that the completion of these projects will lead to the roll-out of new electronic products containing eyescreen® as their cornerstone technology.

Encouraging discussions continue with global digital camera manufacturers, where eyescreen® can be used as an electronic viewfinder for the next generation of cameras for the global market.

MED has continued to develop target markets for our display, with customers and potential partners beginning to recognise the product's superior image quality, lower power demand, lightweight construction and ease of integration, culminating in the signing of two Memorandum of Understanding ("MOU") contracts with leading global partners, post the period end.

Kaga Components Ltd, part of the Kaga Electronics Group, one of Japan's leading electronic component manufacturers, has signed a MOU with MED to use eyescreen® in their designs for electronic view finder modules, intended for the next generation of digital cameras being manufactured in the region. The MOU offers eyescreen® access to a substantial market as 120 million digital cameras were manufactured world wide last year. 

A second MOU was announced with Universal Scientific Industrial Co. Ltd (USI), a leading design and manufacturing services company, producing electronic hardware modules for a wide variety of applications from basic components to PC motherboards. This agreement sets out a collaborative framework for USI and MED to produce display modules for head mounted display units, targeted at the growing mobile media accessories market.

The Board is delighted that the Company is working with partners of this calibre. Both MOUs demonstrate that we are beginning to enjoy traction in the electronic view finder, and head-mounted display markets, two key target areas for the application of eyescreen®.

Management/Board Changes

During the period, we strengthened the Board with the appointment of Glenn Collinson as Non-Executive Director in April 2008. Glenn's knowledge of the semiconductor industry and his enthusiasm has been an asset to the Company and we look forward to his future contribution to the success of MED.

The senior management team has also been strengthened by the appointment of Kaz Okamura as VP of Sales for Japan and Echo Li as VP of Sales for Asia. Both are experienced individuals who bring with them a track record of success in their respective regions.

Following the departure of Paul Van Eynde as Sales and Marketing Director of MED, Bill Miller, Chief Executive, assumed the responsibilities for the sales and marketing function of the business, and Graeme Walker, Finance Director, took on the role of day-to-day management of MED. The Company has identified potential candidates for the role of Sales and Marketing Director and will make an appointment in due course.

Financial Review

Revenues for the period were £377,000 (2007: £0)

Pre-tax losses were £3.8m (2007: £3.1m)

Cash and Cash equivalents as at 30 June 2008: £2.1m (2007: £3.3m)

Cash and cash equivalents as at 29 September 2008 was £1.3m

Outlook

MED's technology provides unique benefits which are being demanded by the market. Progress with our customer base is slower than expected but is progressing and management continue to believe that the market opportunities for the Company remain very significant.

The directors have prepared detailed cash flow projections for the period to 31 December 2009 which demonstrate that the Group's cash resources are expected to be sufficient to enable it to continue to trade and meet its liabilities as they fall due for at least twelve months from the date of approval of the half-yearly report. However, a key element underpinning these cash flow forecasts is the completion of a corporate transaction to re-finance the business. Although the directors are in discussions with interested parties, there can be no certainty that a transaction will occur, and should it not go ahead, the Group's existing cash resources are likely to be exhausted by mid-December 2008.

G Elliott

Chairman

  Responsibility Statement of the directors in respect of the half yearly financial report

We confirm that to the best of our knowledge:

the condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU; 

the interim management report includes a fair review of the information required by: 

(a) DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
 
(b) DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.

Bill Miller

Graeme N Walker

Chief Operating Officer

Chief Finance Officer

  Condensed consolidated income statement

for the six month period ended 30 June 2008

6 months

6 months 

Year ended

 to 30 June 

to 30 June 

31 December 

2008

2007

2007

(unaudited)

(unaudited)

(audited)

Note

£000

£000

£000

Revenue

377

-

65

Changes in inventories of finished goods and work in progress

(117)

-

213

Raw materials and consumables used

(1,108)

(697)

(2,009)

Employee benefit cost

(1,344)

(1,371)

(2,774)

Depreciation and amortisation expenses

(608)

(166)

(721)

Other expenses

(1,098)

(882)

(1,871)

Operating loss before financing costs

(3,898)

(3,116)

(7,097)

Financial income

96

42

140

Financial expense

(42)

(36)

(152)

Net finance income/(expense)

54

6

(12)

Loss before income taxes

(3,844)

(3,110)

(7,109)

Income tax credit

2

580

883

883

Loss for the period attributable to equity holders of the Company

(3,264)

(2,227)

(6,226)

Loss per ordinary share (pence)

Basic and diluted loss per share (pence)

3

5.5p

5.1p

13.1p

Condensed consolidated statement of recognised income and expense

for the six month period ended 30 June 2008

6 months

6 months 

Year ended

 to 30 June 

to 30 June 

31 December 

2008

2007

2007

(unaudited)

(unaudited)

(audited)

£000

£000

£000

Foreign exchange translation differences for foreign operations

(44)

(35)

77

Income and expense recognised directly in equity

(44)

(35)

77

Loss for the period

(3,264)

(2,227)

(6,226)

Total recognised income and expense for the period attributable to equity holders of the Company 

(3,308)

(2,262)

(6,149)

   

Condensed consolidated balance sheet

as at 30 June 2008

As at

As at

As at

30 June 

30 June

31 December

2008

2007

2007

(unaudited)

(unaudited)

(audited)

£000

£000

£000

ASSETS

Property, plant and equipment

5,430

5,521

5,673

Intangible assets

1,909

2,005

2,020

Total non-current assets

7,339

7,526

7,693

Current assets

Inventories

96

-

213

Trade and other receivables

937

273

266

Cash and cash equivalents

2,146

3,330

6,293

Total current assets

3,179

3,603

6,772

Total assets

10,518

11,129

14,465

LIABILITIES

Loans and borrowings

382

1,141

380

Trade and other payables

556

415

927

Deferred income

381

-

380

Total current liabilities

1,319

1,556

1,687

Non-current liabilities

Loans and borrowings

182

546

367

Deferred income

1,907

2,477

2,098

Total non-current liabilities

2,089

3,023

2,465

Total liabilities

3,408

4,579

4,152

Net assets

7,110

6,550

10,313

Equity

Issued capital

11,558

11,401

11,558

Share premium account

20,149

12,789

20,149

Other reserve

6,814

6,814

6,814

Translation reserve

16

(52)

60

Profit and loss account

(31,427)

(24,402)

(28,268)

Total equity

7,110

6,550

10,313

  

Condensed consolidated cash flow statement

for the six month period ended 30 June 2008

6 months to

6 months to

12 months to

30 June

30 June 

31 December

2008

2007

2007

(unaudited)

(unaudited)

(audited)

£000

£000

£000

Cash flows from operating activities

Loss for the period

(3,264)

(2,227)

(6,226)

Adjustments for:

Depreciation

490

49

466

Amortisation

118

118

255

Foreign exchange loss

(44)

(36)

(366)

Equity settled share based payment transactions

105

127

260

Amortisation of grant income

(190)

-

(188)

Development expenditure capitalised

-

(57)

(57)

Net finance income

(54)

(6)

(60)

Income tax income

(580)

(883)

(883)

Operating loss before changes in working capital 

(3,419)

(2,915)

(6,799)

Decrease/(increase) in inventories

117

-

(213)

(Increase)/decrease in trade and other receivables

(671)

697

704

(Decrease)/increase in trade and other payables

(371)

136

(78)

Interest paid

(42)

(36)

(80)

Interest received

96

42

140

Income tax received

580

883

883

Cash used by operations

(3,710)

(1,193)

(5,443)

CASH FLOWS FROM INVESTING ACTIVITIES

Inward investment grants received

-

2,477

2,667

Acquisition of property, plant and equipment and intangible assets

(254)

(1,085)

(1,365)

Net cash flow from investing activities

(254)

1,392

1,302

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from the issue of share capital

-

-

7,517

Secured loan received

-

1,000

1,000

Repayment of borrowings

(158)

(163)

(330)

Repayment of finance lease liabilities

(25)

(50)

(97)

Net cash from investing activities

(183)

787

8,090

Net (decrease)/increase in cash and cash equivalents

(4,147)

986

3,949

Cash and cash equivalents at start of period

6,293

2,344

2,344

Cash and cash equivalents at end of period

2,146

3,330

6,293

  

Notes

(forming part of the financial statements)

1. Accounting policies - basis of preparation

The condensed interim financial statements set out above contain the interim financial information of MicroEmissive Displays Group PLC ("the Company") and its subsidiaries (together referred to as "the Group") for the six month period ended 30 June 2008. 

The financial information set out in these interim financial statements has been prepared in compliance with IAS 34 Interim Financial Reporting as adopted by the EU. They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group as at and for the year ended 31 December 2007. The condensed consolidated financial statements were approved by the Board of Directors on 29 September 2008.

The comparative figures for the financial year ended 31 December 2007 are not the Company's statutory accounts for that financial year. Those accounts have been reported on by the Company's auditors and delivered to the registrar of companies. The report of the auditors was i) unqualified ii) did not include a reference to any matters to which the auditors drew attention by the way of emphasis without qualifying their report iii) did not contain a statement under section 237 (2) or (3) of the Companies Act 1985.

The Interim condensed consolidated financial statements for the current and comparative periods are unaudited.

The directors have prepared detailed cash flow projections for the period to 31 December 2009 which demonstrate that the Group's cash resources are expected to be sufficient to enable it to continue to trade and meet its liabilities as they fall due for at least twelve months from the date of approval of the half-yearly report. The key element underpinning the cash flow forecasts is the completion of a corporate transaction and the directors are currently in negotiations with interested parties. Completion of the transaction is, however, not certain and should it not go ahead the directors forecast that the Group's cash resources will be used by mid-December 2008.

The uncertainty in relation to this matter may cast significant doubt on the Group's ability to continue as a going concern. The Group may, therefore, be unable to continue realising its assets and discharging its liabilities in the normal course of business but the half-yearly report does not include any adjustments that would result from the going concern basis of preparation being inappropriate.

2. Taxation

No provision for income taxes is required due to the availability of tax losses. At 30 June 2008, corporation tax losses and other deferred tax temporary differences were approximately £13,000,000. The tax credit is in respect of research tax allowances received.

 3. Loss per share

6 months to

6 months to 

Year ended

30 June 

30 June

31 December 

2008

2007

2007

£000

£000

£000

(unaudited)

(unaudited)

(audited)

Loss for the period attributable to equity shareholders (basic and diluted)

(3,264)

(2,227)

(6,226)

Basic loss per share - pence

5.5p

5.1p

13.1p

Diluted loss per share - pence

5.5p

5.1p

13.1p

The weighted average number of ordinary shares used in the calculation of basic and diluted earnings per share for each period were calculated as follows:

6 months to

6 months to 

Year ended

30 June 

30 June

31 December 

2008

2007

2007

No of Shares

No of Shares

No of Shares

'000

'000

'000

Issued ordinary shares at start of the period

59,352

43,632

43,632

Effect of shares issued during the period 

-

-

3,765

Weighted average number of ordinary shares for the period (basic and diluted)

59,352

43,632

47,397

 

4. Reserves 

Share 

Share

Translation

Merger

Retained

Capital

Premium

Reserve

Reserve

Earnings

Total

£000

£000

£000

£000

£000

£000

Balance at 1 January 2007

11,401

12,789

(17)

6,814

(22,302)

8,685

Total recognised income and expense

-

-

(35)

-

(2,227)

(2,262)

Share based payments

-

-

-

-

127

127

Balance at 30 June 2007

11,401

12,789

(52)

6,814

(24,402)

6,550

Total recognised income and expense

-

-

112

-

(3,999)

(3,887)

Issue of ordinary shares

157

7,360

-

-

-

7,517

Share based payments

-

-

-

-

133

133

Balance at 31 December 2007

11,558

20,149

60

6,814

(28,268)

10,313

Total recognised income and expense

-

-

(44)

-

(3,264)

(3,308)

Share based payments

-

-

-

-

105

105

Balance at 30 June 2008

11,558

20,149

16

6,814

(31,427)

7,110

5. Related parties

 

Identity of Related Parties

The Company has a related party relationship with its subsidiaries and with its directors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FKKKPCBKKCCN
Date   Source Headline
17th Dec 20207:00 amRNSChange of ticker
2nd Dec 20207:00 amRNSChange of auditor
30th Oct 20207:00 amRNSVoluson SWIFT receives FDA clearance
30th Sep 20207:00 amRNSGE Healthcare launches new ultrasound AI software
21st Sep 20207:00 amRNSChange of Registered Office
18th Sep 20207:00 amRNSFDA filing submitted for second ScanNavAI software
16th Sep 20207:00 amRNSFormation of Nomination Committee
6th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20207:00 amRNSNotice of Results
13th Jul 20207:00 amRNSTrading Update
18th Jun 202011:30 amRNSResult of AGM
18th May 20207:00 amRNSNotice of AGM and publication of Annual Report
7th May 20205:29 pmRNSHolding(s) in Company
7th May 202011:03 amRNSHolding(s) in Company
6th May 20209:36 amRNSDirector dealings
4th May 202011:27 amRNSResult of General Meeting & Total Voting Rights
24th Apr 20202:57 pmRNSGrant of Options
22nd Apr 20207:00 amRNSBodyWorks COVID-19 Ultrasound Simulator case study
17th Apr 20203:22 pmRNSPlacing to raise £5.2m and Notice of GM
3rd Apr 20207:00 amRNSNHS Nightingale ExCel Hospital
26th Mar 20207:00 amRNSFinal Results
25th Mar 20207:00 amRNSCOVID-19 update; COVID-19 training module launch
4th Mar 20207:00 amRNSISO13485 certification for medical devices
4th Mar 20207:00 amRNSDirector/PDMR Shareholding
28th Feb 20207:00 amRNSNotice of Results
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
29th Jan 20207:00 amRNSMinisterial visit to Intelligent Ultrasound HQ
8th Jan 20207:00 amRNSTrading Update
26th Nov 20197:00 amRNSDirectorate Changes
25th Nov 20197:00 amRNSContingent Liability Update
17th Oct 20191:00 pmRNSAgreement with FUJIFILM SonoSite, Inc.
23rd Sep 20197:00 amRNSUltrasound AI database exceeds four million images
4th Sep 20197:00 amRNSClarification of change of holding
2nd Sep 201911:48 amRNSHolding(s) in Company
30th Aug 20196:17 pmRNSHolding(s) in Company
28th Aug 20195:16 pmRNSHolding(s) in Company
28th Aug 20199:12 amRNSDirector/PDMR Shareholding
27th Aug 201911:45 amRNSResult of General Meeting and Open Offer
8th Aug 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
31st Jul 20197:00 amRNSHalf-year Report
25th Jul 20197:00 amRNSCollaboration with National Imaging Academy Wales
10th Jul 20197:00 amRNSTrading update
4th Jul 20197:46 amRNSFirst OEM agreement for AI based imaging software
23rd May 20193:14 pmRNSResult of AGM
23rd May 20197:00 amRNSAGM Statement
16th May 20197:00 amRNSFirst live demonstration of ScanNav AnatomyGuide
30th Apr 20197:00 amRNSNotice of Annual General Meeting
28th Mar 20197:00 amRNSFinal Results
19th Feb 20197:00 amRNSNotice of Results
24th Jan 20197:00 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.